For immediate release Johnson & Johnson reports Q3 2025 results; raises 2025 sales outlook • 2025 Third-Quarter reported sales growth of 6.8% to $24.0 Billion with operational growth of 5.4%* and adjusted operational growth of 4.4%* • 2025 Third-Quarter reflects earnings per share (EPS) of $2.12 and adjusted EPS of $2.80 • Significant innovation including approvals of INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYA subcutaneous in ulcerative colitis, submission of icotrokinra for plaque psoriasis, landmark data for RYBREVANT plus LAZCLUZE overall survival in non-small cell lung cancer, and DanGer Shock long-term survival benefit of Impella Heart Pump • Company increases full year estimated reported sales 5 guidance to $93.7B or 5.7% at the midpoint; reaffirms full year adjusted EPS 4 guidance of $10.85 at the midpoint, absorbing higher tax costs New Brunswick, N.J. (October 14, 2025) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025. “Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, Johnson & Johnson is in a new era of accelerated growth and innovation, with pioneering treatments that will continue to transform lives.” Overall financial results Q3 ($ in Millions, except EPS) 2025 2024 % Change Reported Sales $23,993 $22,471 6.8% Net Earnings $5,152 $2,694 91.2% EPS (diluted) $2.12 $1.11 91.0% Q3 Non-GAAP* ($ in Millions, except EPS) 2025 2024 % Change Operational Sales 1,2 5.4% Adjusted Operational Sales 1,3 4.4% Adjusted Net Earnings 1,4 $6,801 $5,876 15.7% Adjusted EPS (diluted)1,4 $2.80 $2.42 15.7% Free Cash Flow 6,7 ~$14,200 $14,471 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com -- 1 of 22 -- 6 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 7 Third-quarter YTD 2025 is estimated as of October 14, 2025 Note: values may have been rounded Regional sales results Q3 % Change ($ in Millions) 2025 2024 Reported Operational 1,2 Currency Adjusted Operational 1,3 U.S. $13,708 $12,909 6.2% 6.2 - 4.4 International 10,285 9,562 7.6 4.4 3.2 4.4 Worldwide $23,993 $22,471 6.8% 5.4 1.4 4.4 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Segment sales results Q3 % Change ($ in Millions) 2025 2024 Reported Operational 1,2 Currency Adjusted Operational 1,3 Innovative Medicine $15,563 $14,580 6.8% 5.3 1.5 3.7 MedTech 8,430 7,891 6.8 5.6 1.2 5.7 Worldwide $23,993 $22,471 6.8% 5.4 1.4 4.4 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Third-Quarter 2025 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 5.3%*, with net acquisitions and divestitures positively impacting growth by 1.6% due to CAPLYTA. Growth was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience. Growth was partially offset by an approximate (1,070) basis points impact from STELARA in Immunology, as well as IMBRUVICA in Oncology. MedTech MedTech worldwide operational sales grew 5.6%*, with net acquisitions and divestitures negatively impacting growth by 0.1%. Growth was primarily driven by electrophysiology products, Abiomed and Shockwave in Cardiovascular, wound closure products in General Surgery, as well as Surgical Vision. -- 2 of 22 -- Full-year 2025 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. ($ in Billions, except EPS) October 2025 July 2025 Adjusted Operational Sales1,2,5 Change vs. Prior Year / Mid-point 3.5% – 4.0% / 3.8% 3.2% – 3.7% / 3.5% Operational Sales2,5 / Mid-point Change vs. Prior Year / Mid-point $93.0B – $93.4B / $93.2B 4.8% – 5.3% / 5.1% $92.7B – $93.1B / $92.9B 4.5% – 5.0% / 4.8% Estimated Reported Sales3,5 / Mid-point Change vs. Prior Year / Mid-point $93.5B – $93.9B / $93.7B 5.4% – 5.9% / 5.7% $93.2B – $93.6B / $93.4B 5.1% – 5.6% / 5.4% Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point $10.63 – $10.73 / $10.68 6.5% – 7.5% / 7.0% $10.63 – $10.73 / $10.68 6.5% – 7.5% / 7.0% Adjusted EPS (Diluted)3,4 / Mid-point Change vs. Prior Year / Mid-point $10.80 – $10.90 / $10.85 8.2% – 9.2% / 8.7% $10.80 – $10.90 / $10.85 8.2% – 9.2% / 8.7% 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: Oct 2025 = $1.13 and July 2025 = $1.13 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine Note: percentages may have been rounded Other modeling considerations will be provided on the webcast Notable announcements in the quarter: The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News, as well as Innovative Medicine Newsroom, MedTech News & Events, and www.factsabouttalc.com. Regulatory U.S. FDA approves TREMFYA (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor1 Press Release TREMFYA (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen Press Release Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG) Press Release Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis Press Release -- 3 of 22 -- European Commission approves DARZALEX (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma Press Release European Commission approves IMBRUVICA (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant Press Release Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis Press Release Data Releases Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress1 Press Release Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill1 Press Release TREMFYA (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis 1 Press Release Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses1 Press Release Johnson & Johnson’s investigational seltorexant shows numerically higher response in patients with depression with insomnia symptoms, with fewer side effects compared to quetiapine XR Press Release TECVAYLI plus DARZALEX FASPRO treatment demonstrates 100 percent overall response rate in transplant-eligible patients newly diagnosed with multiple myeloma Press Release Icotrokinra shows superiority to deucravacitinib in first reported head- to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis Press Release Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting Press Release Data published in The New England Journal of Medicine demonstrate RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) is re- setting survival expectations in first-line EGFR-mutated lung cancer Press Release RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non- small cell lung cancer Press Release New real-world data elevating patient perspectives highlight the need for scientific advancement in maternal fetal immunology at ISUOG 2025 Press Release Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE Platform, at 2025 European Society of Cardiology (ESC) Congress Press Release New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump Press Release Johnson & Johnson showcases latest advancements in Alzheimer's research at AAIC 2025 Press Release Product Launch U.S. FDA approval of INLEXZO (gemcitabine intravesical system) set to transform how certain bladder cancers are treated Press Release Johnson & Johnson Launches VIRTUGUIDE AI-Powered Patient- Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions Press Release -- 4 of 22 -- Other Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors Press Release 1 Subsequent to the quarter Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations. About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com. Non-GAAP financial measures: * “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non- GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results. Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results. Note to investors concerning forward-looking statements: This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained -- 5 of 22 -- by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. -- 6 of 22 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2025 2024 Total Operations Currency 2025 2024 Total Operations Currency Sales to customers by segment of business Innovative Medicine U.S. 9,402 $ 8,871 6.0 % 6.0 - 26,655 $ 24,993 6.7 % 6.7 - International 6,161 5,709 7.9 4.3 3.6 17,983 17,639 1.9 1.3 0.6 15,563 14,580 6.8 5.3 1.5 44,638 42,632 4.7 4.5 0.2 MedTech U.S. 4,306 4,038 6.6 6.6 - 12,902 12,105 6.6 6.6 - International 4,124 3,853 7.0 4.5 2.5 12,089 11,564 4.5 3.9 0.6 8,430 7,891 6.8 5.6 1.2 24,991 23,669 5.6 5.3 0.3 U.S. 13,708 12,909 6.2 6.2 - 39,557 37,098 6.6 6.6 - International 10,285 9,562 7.6 4.4 3.2 30,072 29,203 3.0 2.3 0.7 Worldwide 23,993 $ 22,471 6.8 % 5.4 1.4 69,629 $ 66,301 5.0 % 4.7 0.3 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. THIRD QUARTER NINE MONTHS Percent Change -- 7 of 22 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2025 2024 Total Operations Currency 2025 2024 Total Operations Currency Sales to customers by geographic area U.S. 13,708 $ 12,909 6.2 % 6.2 - 39,557 $ 37,098 6.6 % 6.6 - Europe 5,440 4,914 10.7 4.4 6.3 15,937 15,291 4.2 1.5 2.7 Western Hemisphere excluding U.S. 1,231 1,173 4.9 7.3 (2.4) 3,604 3,579 0.7 7.6 (6.9) Asia-Pacific, Africa 3,614 3,475 4.0 3.4 0.6 10,531 10,333 1.9 1.8 0.1 International 10,285 9,562 7.6 4.4 3.2 30,072 29,203 3.0 2.3 0.7 Worldwide 23,993 $ 22,471 6.8 % 5.4 1.4 69,629 $ 66,301 5.0 % 4.7 0.3 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. THIRD QUARTER NINE MONTHS Percent Change -- 8 of 22 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 23,993 $ 100.0 22,471 $ 100.0 6.8 Cost of products sold 7,303 30.4 6,963 31.0 4.9 Gross Profit 16,690 69.6 15,508 69.0 7.6 Selling, marketing and administrative expenses 5,922 24.7 5,478 24.3 8.1 Research and development expense 3,672 15.3 4,952 22.0 (25.8) Interest (income) expense, net 18 0.1 (99) (0.4) Other (income) expense, net (478) (2.0) 1,798 8.0 Restructuring 63 0.3 41 0.2 Earnings before provision for taxes on income 7,493 31.2 3,338 14.9 124.5 Provision for taxes on income 2,341 9.7 644 2.9 263.5 Net earnings 5,152 $ 21.5 2,694 $ 12.0 91.2 Net earnings per share (Diluted) 2.12 $ 1.11 $ 91.0 Average shares outstanding (Diluted) 2,428.6 2,427.9 Effective tax rate 31.2 % 19.3 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 8,436 $ 35.2 7,277 $ 32.4 15.9 Net earnings 6,801 $ 28.3 5,876 $ 26.1 15.7 Net earnings per share (Diluted) 2.80 $ 2.42 $ 15.7 Effective tax rate 19.4 % 19.3 % (1) See Reconciliation of Non-GAAP Financial Measures. THIRD QUARTER 2025 2024 -- 9 of 22 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 69,629 $ 100.0 66,301 $ 100.0 5.0 Cost of products sold 22,288 32.0 20,343 30.7 9.6 Gross Profit 47,341 68.0 45,958 69.3 3.0 Selling, marketing and administrative expenses 16,923 24.3 16,416 24.8 3.1 Research and development expense 10,413 15.0 11,934 18.0 (12.7) In-process research and development impairments - - 194 0.3 Interest (income) expense, net (62) (0.1) (433) (0.7) Other (income) expense, net (7,692) (11.1) 4,855 7.3 Restructuring 144 0.2 192 0.3 Earnings before provision for taxes on income 27,615 39.7 12,800 19.3 115.7 Provision for taxes on income 5,927 8.6 2,165 3.3 173.8 Net earnings 21,688 $ 31.1 10,635 $ 16.0 103.9 Net earnings per share (Diluted) 8.94 $ 4.38 $ 104.1 Average shares outstanding (Diluted) 2,424.8 2,429.5 Effective tax rate 21.5 % 16.9 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 24,635 $ 35.4 23,558 $ 35.5 4.6 Net earnings 20,206 $ 29.0 19,296 $ 29.1 4.7 Net earnings per share (Diluted) 8.33 $ 7.94 $ 4.9 Effective tax rate 18.0 % 18.1 % (1) See Reconciliation of Non-GAAP Financial Measures. NINE MONTHS 2025 2024 -- 10 of 22 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2025 2024 2025 2024 Net Earnings, after tax- as reported $5,152 $2,694 $21,688 $10,635 Pre-tax Adjustments Litigation related 15 2,388 (6,894) 5,466 Intangible Asset Amortization expense 1,048 1,171 3,435 3,355 COVID-19 Vaccine related costs - 4 - 77 Restructuring related 1 168 47 302 207 Medical Device Regulation - 38 - 157 Acquisition, integration and divestiture related 97 328 475 928 (Gains)/losses on securities (387) (37) (327) 374 IPR&D impairments - - - 194 Other 2 - 29 - Tax Adjustments Tax impact on special item adjustments 2 (168) (762) 826 (2,055) Tax legislation and other tax related 874 5 672 (42) Adjusted Net Earnings, after tax $6,801 $5,876 $20,206 $19,296 Average shares outstanding (Diluted) 2,428.6 2,427.9 2,424.8 2,429.5 Adjusted net earnings per share (Diluted) $2.80 $2.42 $8.33 $7.94 Operational adjusted net earnings per share (Diluted) $2.72 $8.24 Notes: 1 2 Third Quarter Nine Months Ended In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $19 million in the fiscal third quarter of 2024 ($100 million Q3 2024 YTD) included the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024. In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) and $28 million in the fiscal third quarter of 2024 ($107 million Q3 2024 YTD) primarily includes costs related to market and product exits. In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs related to asset impairments and market and product exits. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. -- 11 of 22 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 6.8% 6.8% 6.8% U.S. 6.0% 6.6% 6.2% International 7.9% 7.0% 7.6% WW Currency 1.5 1.2 1.4 U.S. - - - International 3.6 2.5 3.2 WW Operational 5.3% 5.6% 5.4% U.S. 6.0% 6.6% 6.2% International 4.3% 4.5% 4.4% Caplyta (1.6) (1.1) U.S. (2.7) (1.9) International 0.0 0.0 All Other Acquisitions and Divestitures (A&D) 0.0 0.1 0.1 U.S. 0.0 0.2 0.1 International 0.0 0.1 0.0 WW Adjusted Operational Ex A&D 3.7% 5.7% 4.4% U.S. 3.3% 6.8% 4.4% International 4.3% 4.6% 4.4% Adjusted Operational Sales Growth THIRD QUARTER 2025 ACTUAL vs. 2024 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 12 of 22 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 4.7% 5.6% 5.0% U.S. 6.7% 6.6% 6.6% International 1.9% 4.5% 3.0% WW Currency 0.2 0.3 0.3 U.S. - - - International 0.6 0.6 0.7 WW Operational 4.5% 5.3% 4.7% U.S. 6.7% 6.6% 6.6% International 1.3% 3.9% 2.3% Shockwave (1.9) (0.6) U.S. (2.9) (0.9) International (0.8) (0.2) Caplyta (1.1) (0.7) U.S. (1.8) (1.2) International 0.0 0.0 All Other Acquisitions and Divestitures (A&D) 0.0 0.3 0.1 U.S. 0.0 0.4 0.1 International 0.1 0.2 0.1 WW Adjusted Operational Ex A&D 3.4% 3.7% 3.5% U.S. 4.9% 4.1% 4.6% International 1.4% 3.3% 2.2% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth NINE MONTHS 2025 ACTUAL vs. 2024 ACTUAL Segments -- 13 of 22 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS INNOVATIVE MEDICINE SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency ONCOLOGY US 3,468 $ 2,816 23.2% 23.2% - 9,866 $ 7,835 25.9% 25.9% - Intl 3,060 2,565 19.3% 14.8% 4.5% 8,652 7,450 16.1% 15.0% 1.1% WW 6,529 5,380 21.3% 19.2% 2.1% 18,519 15,284 21.2% 20.6% 0.6% CARVYKTI US 396 258 53.3% 53.3% - 1,072 565 89.6% 89.6% - Intl 128 27 * * * 260 63 * * * WW 524 286 83.5% 81.4% 2.1% 1,332 629 * * * DARZALEX US 2,088 1,684 24.0% 24.0% - 5,934 4,789 23.9% 23.9% - Intl 1,584 1,332 18.9% 14.7% 4.2% 4,514 3,797 18.9% 17.9% 1.0% WW 3,672 3,016 21.7% 19.9% 1.8% 10,448 8,586 21.7% 21.3% 0.4% ERLEADA US 378 337 12.3% 12.3% - 1,048 940 11.5% 11.5% - Intl 558 453 23.0% 17.6% 5.4% 1,567 1,275 22.9% 21.1% 1.8% WW 936 790 18.4% 15.3% 3.1% 2,615 2,215 18.0% 17.0% 1.0% IMBRUVICA US 211 259 (18.3)% (18.3)% - 685 770 (11.0)% (11.0)% - Intl 483 494 (2.3)% (6.6)% 4.3% 1,453 1,537 (5.4)% (6.4)% 1.0% WW 695 753 (7.8)% (10.6)% 2.8% 2,139 2,307 (7.3)% (7.9)% 0.6% RYBREVANT / LAZCLUZE (3) US 136 68 99.7% 99.7% - 388 156 * * - Intl 61 21 * * * 130 49 * * * WW 198 89 * * * 518 205 * * * TALVEY US 85 64 34.2% 34.2% - 235 173 35.8% 35.8% - Intl 37 12 * * * 79 29 * * * WW 122 75 60.8% 59.1% 1.7% 314 202 55.3% 54.9% 0.4% TECVAYLI US 115 105 9.3% 9.3% - 334 310 7.5% 7.5% - Intl 62 30 * * * 160 93 73.0% 72.6% 0.4% WW 177 135 31.3% 29.9% 1.4% 494 403 22.6% 22.5% 0.1% ZYTIGA / abiraterone acetate US 5 5 (25.0)% (25.0)% - 18 25 (30.4)% (30.4)% - Intl 108 144 (25.1)% (26.8)% 1.7% 365 470 (22.3)% (23.0)% 0.7% WW 113 150 (25.1)% (26.8)% 1.7% 383 496 (22.8)% (23.4)% 0.6% OTHER ONCOLOGY US 56 36 54.6% 54.6% - 153 106 44.8% 44.8% - Intl 39 50 (22.2)% (25.6)% 3.4% 123 136 (9.7)% (10.6)% 0.9% WW 94 86 9.7% 7.7% 2.0% 276 242 14.0% 13.6% 0.4% See footnotes at end of schedule % Change % Change -- 14 of 22 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency IMMUNOLOGY US 2,676 $ 3,068 (12.8)% (12.8)% - 7,377 $ 8,499 (13.2)% (13.2)% - Intl 1,493 1,552 (3.9)% (6.3)% 2.4% 4,492 5,090 (11.8)% (11.5)% (0.3)% WW 4,168 4,621 (9.8)% (10.6)% 0.8% 11,868 13,590 (12.7)% (12.6)% (0.1)% REMICADE US 326 281 16.2% 16.2% - 923 778 18.7% 18.7% - US Exports (4) 19 27 (30.9)% (30.9)% - 63 89 (29.6)% (29.6)% - Intl 132 112 17.7% 16.7% 1.0% 413 380 8.6% 10.4% (1.8)% WW 476 419 13.6% 13.3% 0.3% 1,398 1,246 12.2% 12.7% (0.5)% SIMPONI / SIMPONI ARIA US 309 299 3.6% 3.6% - 906 820 10.5% 10.5% - Intl 377 218 73.0% 69.8% 3.2% 1,130 787 43.5% 44.6% (1.1)% WW 687 516 32.9% 31.5% 1.4% 2,036 1,607 26.7% 27.2% (0.5)% STELARA US 1,022 1,770 (42.3)% (42.3)% - 3,081 5,021 (38.6)% (38.6)% - Intl 549 906 (39.4)% (41.4)% 2.0% 1,768 2,991 (40.9)% (40.8)% (0.1)% WW 1,570 2,676 (41.3)% (42.0)% 0.7% 4,848 8,012 (39.5)% (39.5)% 0.0% TREMFYA US 989 691 43.1% 43.1% - 2,384 1,789 33.3% 33.3% - Intl 434 316 37.4% 33.4% 4.0% 1,181 932 26.7% 26.1% 0.6% WW 1,424 1,007 41.3% 40.1% 1.2% 3,566 2,721 31.0% 30.8% 0.2% OTHER IMMUNOLOGY US 12 1 * * - 21 3 * * - Intl 0 0 - - - 0 0 - - - WW 12 1 * * - 21 3 * * - NEUROSCIENCE US 1,367 1,094 25.0% 25.0% - 3,712 3,250 14.2% 14.2% - Intl 658 662 (0.7)% (2.6)% 1.9% 2,011 2,090 (3.8)% (3.7)% (0.1)% WW 2,024 1,755 15.3% 14.6% 0.7% 5,722 5,340 7.2% 7.2% 0.0% CAPLYTA (5) US 240 - * * - 451 - * * - Intl - - - - - - - - - - WW 240 - * * - 451 - * * - CONCERTA / Methylphenidate US 14 26 (49.2)% (49.2)% - 76 101 (24.9)% (24.9)% - Intl 127 117 9.0% 8.5% 0.5% 376 382 (1.4)% (0.4)% (1.0)% WW 140 142 (1.4)% (1.8)% 0.4% 452 482 (6.3)% (5.5)% (0.8)% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 664 780 (14.9)% (14.9)% - 2,021 2,329 (13.2)% (13.2)% - Intl 267 269 (0.9)% (3.0)% 2.1% 804 830 (3.1)% (3.0)% (0.1)% WW 929 1,049 (11.3)% (11.9)% 0.6% 2,824 3,159 (10.6)% (10.5)% (0.1)% SPRAVATO US 405 243 67.1% 67.1% - 1,047 660 58.7% 58.7% - Intl 53 42 28.9% 23.8% 5.1% 146 120 21.9% 21.4% 0.5% WW 459 284 61.5% 60.8% 0.7% 1,193 780 53.0% 52.9% 0.1% OTHER NEUROSCIENCE US 46 46 0.4% 0.4% - 119 161 (26.4)% (26.4)% - Intl 210 235 (10.7)% (12.3)% 1.6% 684 759 (9.8)% (9.9)% 0.1% WW 256 281 (8.9)% (10.2)% 1.3% 803 920 (12.7)% (12.8)% 0.1% See footnotes at end of schedule % Change % Change -- 15 of 22 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency PULMONARY HYPERTENSION US 815 $ 815 (0.1)% (0.1)% - 2,358 $ 2,324 1.5% 1.5% - Intl 300 287 4.8% 2.0% 2.8% 895 866 3.4% 2.6% 0.8% WW 1,115 1,102 1.1% 0.4% 0.7% 3,253 3,190 2.0% 1.8% 0.2% OPSUMIT / OPSYNVI US 409 417 (1.6)% (1.6)% - 1,175 1,149 2.3% 2.3% - Intl 168 166 1.1% (1.8)% 2.9% 507 506 0.2% (0.7)% 0.9% WW 578 583 (0.8)% (1.7)% 0.9% 1,682 1,655 1.7% 1.4% 0.3% UPTRAVI US 392 379 3.5% 3.5% - 1,139 1,120 1.7% 1.7% - Intl 92 80 15.2% 12.0% 3.2% 272 232 17.0% 16.4% 0.6% WW 484 458 5.6% 5.0% 0.6% 1,411 1,352 4.3% 4.2% 0.1% OTHER PULMONARY HYPERTENSION US 13 21 (36.5)% (36.5)% - 44 56 (21.5)% (21.5)% - Intl 39 39 (1.0)% (2.5)% 1.5% 116 127 (8.9)% (9.1)% 0.2% WW 53 60 (13.1)% (14.1)% 1.0% 160 183 (12.7)% (12.9)% 0.2% INFECTIOUS DISEASES US 326 365 (10.5)% (10.5)% - 961 1,023 (6.0)% (6.0)% - Intl 501 471 6.4% 0.5% 5.9% 1,472 1,599 (7.9)% (9.8)% 1.9% WW 829 836 (0.9)% (4.3)% 3.4% 2,434 2,622 (7.2)% (8.3)% 1.1% EDURANT / rilpivirine US 7 8 (7.9)% (7.9)% - 21 24 (11.8)% (11.8)% - Intl 378 323 16.9% 9.9% 7.0% 1,082 926 16.8% 13.6% 3.2% WW 385 330 16.4% 9.5% 6.9% 1,103 950 16.1% 13.0% 3.1% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 315 355 (11.0)% (11.0)% - 932 990 (5.8)% (5.8)% - Intl 81 94 (13.6)% (18.5)% 4.9% 264 315 (16.1)% (16.6)% 0.5% WW 397 449 (11.6)% (12.6)% 1.0% 1,196 1,305 (8.3)% (8.4)% 0.1% OTHER INFECTIOUS DISEASES US 4 3 57.3% 57.3% - 8 10 (11.0)% (11.0)% - Intl 42 54 (21.2)% (22.3)% 1.1% 126 358 (64.7)% (64.6)% (0.1)% WW 47 56 (17.5)% (18.5)% 1.0% 135 367 (63.3)% (63.2)% (0.1)% CARDIOVASCULAR / METABOLISM / OTHER US 750 713 5.3% 5.3% - 2,381 2,061 15.5% 15.5% - Intl 149 170 (13.1)% (15.6)% 2.5% 461 543 (15.2)% (14.7)% (0.5)% WW 899 884 1.7% 1.2% 0.5% 2,842 2,605 9.1% 9.2% (0.1)% XARELTO US 635 592 7.4% 7.4% - 1,946 1,697 14.7% 14.7% - Intl - - - - - - - - - - WW 635 592 7.4% 7.4% - 1,946 1,697 14.7% 14.7% - OTHER US 115 121 (5.2)% (5.2)% - 435 364 19.4% 19.4% - Intl 149 170 (13.1)% (15.6)% 2.5% 461 543 (15.2)% (14.7)% (0.5)% WW 264 292 (9.8)% (11.3)% 1.5% 896 908 (1.3)% (1.0)% (0.3)% TOTAL INNOVATIVE MEDICINE US 9,402 8,871 6.0% 6.0% - 26,655 24,993 6.7% 6.7% - Intl 6,161 5,709 7.9% 4.3% 3.6% 17,983 17,639 1.9% 1.3% 0.6% WW 15,563 $ 14,580 6.8% 5.3% 1.5% 44,638 $ 42,632 4.7% 4.5% 0.2% See footnotes at end of schedule % Change % Change -- 16 of 22 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS MEDTECH SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency CARDIOVASCULAR US 1,306 $ 1,148 13.8% 13.8% - 3,931 $ 3,292 19.4% 19.4% - Intl 908 819 10.8% 8.4% 2.4% 2,698 2,353 14.6% 13.8% 0.8% WW 2,213 1,966 12.6% 11.6% 1.0% 6,629 5,645 17.4% 17.1% 0.3% ELECTROPHYSIOLOGY US 720 660 9.1% 9.1% - 2,145 2,057 4.3% 4.3% - Intl 698 619 12.6% 10.4% 2.2% 2,064 1,889 9.2% 8.6% 0.6% WW 1,418 1,279 10.8% 9.7% 1.1% 4,209 3,946 6.7% 6.4% 0.3% ABIOMED US 336 293 14.5% 14.5% - 1,035 905 14.3% 14.3% - Intl 86 68 26.8% 20.2% 6.6% 256 207 23.9% 20.7% 3.2% WW 423 362 16.8% 15.6% 1.2% 1,291 1,112 16.1% 15.5% 0.6% SHOCKWAVE(6) US 220 163 34.4% 34.4% - 659 240 * * - Intl 59 66 (11.2)% (12.4)% 1.2% 169 66 * * * WW 278 229 21.2% 20.9% 0.3% 828 306 * * * OTHER CARDIOVASCULAR US 30 30 0.0% 0.0% - 93 89 4.2% 4.2% - Intl 65 66 (1.0)% (2.5)% 1.5% 209 192 9.0% 8.7% 0.3% WW 95 96 (0.7)% (1.7)% 1.0% 302 281 7.5% 7.2% 0.3% ORTHOPAEDICS US 1,396 1,359 2.7% 2.7% - 4,200 4,229 (0.7)% (0.7)% - Intl 878 832 5.6% 1.9% 3.7% 2,620 2,614 0.3% (1.1)% 1.4% WW 2,274 2,191 3.8% 2.4% 1.4% 6,820 6,843 (0.3)% (0.8)% 0.5% HIPS US 262 250 4.7% 4.7% - 796 785 1.3% 1.3% - Intl 144 131 9.7% 5.9% 3.8% 440 435 1.2% 0.0% 1.2% WW 405 381 6.4% 5.1% 1.3% 1,235 1,220 1.3% 0.9% 0.4% KNEES US 216 212 2.1% 2.1% - 673 684 (1.5)% (1.5)% - Intl 160 140 14.3% 10.9% 3.4% 482 463 4.0% 3.0% 1.0% WW 377 352 7.0% 5.6% 1.4% 1,155 1,147 0.7% 0.3% 0.4% TRAUMA US 512 497 3.0% 3.0% - 1,515 1,499 1.1% 1.1% - Intl 281 265 6.4% 2.5% 3.9% 818 786 4.1% 2.7% 1.4% WW 793 761 4.2% 2.9% 1.3% 2,333 2,285 2.1% 1.6% 0.5% SPINE, SPORTS & OTHER US 406 400 1.3% 1.3% - 1,216 1,262 (3.7)% (3.7)% - Intl 293 296 (1.1)% (4.8)% 3.7% 881 930 (5.3)% (6.8)% 1.5% WW 698 696 0.3% (1.3)% 1.6% 2,096 2,191 (4.3)% (5.0)% 0.7% See footnotes at end of schedule % Change % Change -- 17 of 22 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency SURGERY US 1,031 $ 983 4.9% 4.9% - 3,076 $ 2,965 3.8% 3.8% - Intl 1,511 1,451 4.1% 2.2% 1.9% 4,417 4,373 1.0% 0.9% 0.1% WW 2,542 2,434 4.4% 3.3% 1.1% 7,493 7,338 2.1% 2.1% 0.0% ADVANCED US 477 448 6.2% 6.2% - 1,411 1,360 3.7% 3.7% - Intl 688 661 4.2% 2.1% 2.1% 1,991 1,977 0.7% 0.5% 0.2% WW 1,165 1,109 5.0% 3.8% 1.2% 3,402 3,337 1.9% 1.8% 0.1% GENERAL US 555 535 3.8% 3.8% - 1,666 1,605 3.8% 3.8% - Intl 823 791 4.0% 2.2% 1.8% 2,426 2,397 1.2% 1.3% (0.1)% WW 1,378 1,325 3.9% 2.9% 1.0% 4,092 4,001 2.3% 2.3% 0.0% VISION US 571 549 4.2% 4.2% - 1,694 1,619 4.7% 4.7% - Intl 828 751 10.2% 7.5% 2.7% 2,354 2,224 5.8% 5.0% 0.8% WW 1,400 1,300 7.7% 6.1% 1.6% 4,048 3,843 5.3% 4.8% 0.5% CONTACT LENSES / OTHER US 456 441 3.5% 3.5% - 1,337 1,288 3.8% 3.8% - Intl 562 527 6.6% 3.4% 3.2% 1,565 1,508 3.8% 2.4% 1.4% WW 1,018 968 5.2% 3.5% 1.7% 2,902 2,796 3.8% 3.1% 0.7% SURGICAL US 116 108 7.0% 7.0% - 358 331 8.0% 8.0% - Intl 266 225 18.7% 17.1% 1.6% 789 717 10.1% 10.3% (0.2)% WW 383 333 14.9% 13.8% 1.1% 1,147 1,048 9.4% 9.6% (0.2)% TOTAL MEDTECH US 4,306 4,038 6.6% 6.6% - 12,902 12,105 6.6% 6.6% - Intl 4,124 3,853 7.0% 4.5% 2.5% 12,089 11,564 4.5% 3.9% 0.6% WW 8,430 $ 7,891 6.8% 5.6% 1.2% 24,991 $ 23,669 5.6% 5.3% 0.3% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE (4) Reported as U.S. sales (5) Acquired with Intra-Cellular Therapies on April 2, 2025 (6) Due to the timing of the integration of the US and foreign affiliates in the year of acquisition (2024), prior quarter (Q3 2024) Shockwave International revenue includes ~$20M of sales that should be reflected in the U.S. business. Year-to-date and total Shockwave sales are not impacted, and the amount was immaterial to recast prior year reporting. Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely % Change % Change -- 18 of 22 -- Innovative Medicine Third Quarter Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Third Quarter Sept 28, 2025 Non-GAAP Cost of products sold 3,672 $ (568) (11) 3,093 Selling, marketing and admin expenses 2,869 2,869 Research and development expense 2,944 2,944 Other segment items (368) 5 (48) 174 (1) (238) Adjusted Income Before Tax by Segment 6,446 568 (5) - 59 (174) - 1 6,895 MedTech Third Quarter Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Third Quarter Sept 28, 2025 Non-GAAP Cost of products sold 3,612 $ (480) (12) (1) 3,119 Selling, marketing and admin expenses 2,801 2,801 Research and development expense 728 728 Other segment items 2 5 (156) (48) 213 (1) 15 Adjusted Income Before Tax by Segment 1,287 480 (5) 168 49 (213) - 1 1,767 Expenses not allocated to segments Third Quarter Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Third Quarter Sept 28, 2025 Non-GAAP Cost of products sold 19 $ 19 Selling, marketing and admin expenses 252 252 Research and development expense - - Other segment items (31) (25) 11 (45) Adjusted Income Before Tax by Segment (240) - 25 - (11) - - - (226) Johnson & Johnson Consolidated Third Quarter Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Third Quarter Sept 28, 2025 Non-GAAP Cost of products sold 7,303 $ (1,048) (12) (12) 6,231 Selling, marketing and admin expenses 5,922 5,922 Research and development expense 3,672 3,672 Other (Income) / Expense (478) (15) (93) (85) 387 (2) (286) In-process research and development impairments - - Interest (Income)/Expense 18 18 Restructuring 63 (63) - Adjusted Income Before Tax 7,493 1,048 15 168 97 (387) - 2 8,436 Provision for taxes on income 2,341 193 3 34 16 (87) (874) 9 1,635 Net Earnings 5,152 855 12 134 81 (300) 874 (7) 6,801 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date -- 19 of 22 -- Innovative Medicine Third Quarter Sept 29, 2024 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Third Quarter Sept 29, 2024 Non-GAAP Cost of products sold 3,549 $ (695) (2) 2,852 Selling, marketing and admin expenses 2,491 2,491 Research and development expense 4,213 (2) 4,211 Other segment items (155) (356) (19) (6) 41 (495) Adjusted Income Before Tax by Segment 4,482 695 356 19 6 (41) - 4 - 5,521 MedTech Third Quarter Sept 29, 2024 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Third Quarter Sept 29, 2024 Non-GAAP Cost of products sold 3,381 $ (476) (6) (156) (16) 2,727 Selling, marketing and admin expenses 2,723 (3) 2,720 Research and development expense 739 (36) (19) 684 Other segment items (11) (19) (22) (85) (4) (141) Adjusted Income Before Tax by Segment 1,059 476 19 28 277 4 38 - - 1,901 Expenses not allocated to segments Third Quarter Sept 29, 2024 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Third Quarter Sept 29, 2024 Non-GAAP Cost of products sold 33 $ 33 Selling, marketing and admin expenses 264 264 Research and development expense - - Other segment items 1,906 (2,013) (45) (152) Adjusted Income Before Tax by Segment (2,203) - 2,013 - 45 - - - - (145) Johnson & Johnson Consolidated Third Quarter Sept 29, 2024 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Third Quarter Sept 29, 2024 Non-GAAP Cost of products sold 6,963 $ (1,171) (6) (156) (16) (2) 5,612 Selling, marketing and admin expenses 5,478 (3) 5,475 Research and development expense 4,952 (36) (19) (2) 4,895 Other (Income) / Expense 1,798 (2,388) (136) 37 (689) In-process research and development impairments - - Interest (Income)/Expense (99) (99) Restructuring 41 (41) - Adjusted Income Before Tax 3,338 1,171 2,388 47 328 (37) 38 4 - 7,277 Provision for taxes on income 644 169 527 9 59 (9) 6 1 (5) 1,401 Net Earnings 2,694 1,002 1,861 38 269 (28) 32 3 5 5,876 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date -- 20 of 22 -- Year to Date Innovative Medicine Nine Months Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Nine Months Sept 28, 2025 Non-GAAP Cost of products sold 11,670 $ (2,002) (24) 9,644 Selling, marketing and admin expenses 7,919 7,919 Research and development expense 8,361 8,361 Other segment items (520) 74 (275) 164 (14) (571) Adjusted Income Before Tax by Segment 17,208 2,002 (74) - 299 (164) - 14 19,285 MedTech Nine Months Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Nine Months Sept 28, 2025 Non-GAAP Cost of products sold 10,576 $ (1,433) (35) (52) 9,056 Selling, marketing and admin expenses 8,319 8,319 Research and development expense 2,052 37 2,089 Other segment items 132 (78) (267) (155) 163 (15) (220) Adjusted Income Before Tax by Segment 3,912 1,433 78 302 170 (163) - 15 5,747 Expenses not allocated to segments Nine Months Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Nine Months Sept 28, 2025 Non-GAAP Cost of products sold 42 $ 42 Selling, marketing and admin expenses 685 685 Research and development expense - - Other segment items (7,222) 6,898 (6) (330) Adjusted Income Before Tax by Segment 6,495 - (6,898) - 6 - - - (397) Johnson & Johnson Consolidated Nine Months Sept 28, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Nine Months Sept 28, 2025 Non-GAAP Cost of products sold 22,288 $ (3,435) (35) (76) 18,742 Selling, marketing and admin expenses 16,923 16,923 Research and development expense 10,413 37 10,450 Other (Income) / Expense (7,692) 6,894 (123) (436) 327 (29) (1,059) In-process research and development impairments - - Interest (Income)/Expense (62) (62) Restructuring 144 (144) - Adjusted Income Before Tax 27,615 3,435 (6,894) 302 475 (327) - 29 24,635 Provision for taxes on income 5,927 603 (1,541) 58 118 (73) (672) 9 4,429 Net Earnings 21,688 2,832 (5,353) 244 357 (254) 672 20 20,206 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions -- 21 of 22 -- Innovative Medicine Nine Months Sept 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Nine Months Sept. 29, 2024 Non-GAAP Cost of products sold 10,522 $ (2,087) (8) 8,427 Selling, marketing and admin expenses 7,594 7,594 Research and development expense 9,831 (19) 9,812 Other segment items (225) (399) (194) (100) (54) 26 (50) (996) Adjusted Income Before Tax by Segment 14,910 2,087 399 194 100 54 (26) - 77 - 17,795 MedTech Nine Months Sept 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Nine Months Sept. 29, 2024 Non-GAAP Cost of products sold 9,749 $ (1,268) (15) (206) (66) 8,194 Selling, marketing and admin expenses 7,976 (12) 7,964 Research and development expense 2,103 (69) (79) 1,955 Other segment items 173 (15) (92) (472) (48) (454) Adjusted Income Before Tax by Segment 3,668 1,268 15 - 107 747 48 157 - - 6,010 Expenses not allocated to segments Nine Months Sept 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Nine Months Sept. 29, 2024 Non-GAAP Cost of products sold 72 $ 72 Selling, marketing and admin expenses 846 846 Research and development expense - - Other segment items 4,860 (5,052) (127) (352) (671) Adjusted Income Before Tax by Segment (5,778) - 5,052 - - 127 352 - - - (247) Johnson & Johnson Consolidated Nine Months Sept 29, 2024 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related Nine Months Sept. 29, 2024 Non-GAAP Cost of products sold 20,343 $ (3,355) (15) (206) (66) (8) 16,693 Selling, marketing and admin expenses 16,416 (12) 16,404 Research and development expense 11,934 (69) (79) (19) 11,767 Other (Income) / Expense 4,855 (5,466) (653) (374) (50) (1,688) In-process research and development impairments 194 (194) - Interest (Income)/Expense (433) (433) Restructuring 192 (192) - Adjusted Income Before Tax 12,800 3,355 5,466 194 207 928 374 157 77 - 23,558 Provision for taxes on income 2,165 473 1,224 43 42 222 5 29 17 42 4,262 Net Earnings 10,635 2,882 4,242 151 165 706 369 128 60 (42) 19,296 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Year to Date -- 22 of 22 --